Key result
Oral beta-blocker therapy turned T-wave alternans negative in 31% of patients with non-ischemic heart disease and significantly decreased alternans voltage in the remaining patients (p<0.001).
Why the study?
Does oral beta-blocker therapy improve T-wave alternans and cardiac sympathetic nervous system function in patients with non-ischemic heart disease?
Observational (n=26)
Open-label
No
Does oral beta-blocker therapy improve T-wave alternans and cardiac sympathetic nervous system function in patients with non-ischemic heart disease?
p-value: p=<0.001
Beta-blocker therapy improves T-wave alternans in non-ischemic heart disease, and this improvement correlates with enhanced cardiac sympathetic nervous system function and left ventricular systolic function.
Beta-blockers may improve TWA via sympathetic effects in non-ischemic disease; leaves open outcome benefits and practice change.
The purpose of this study was to test a hypothesis that T-wave alternans (TWA) is improved in association with an improvement in cardiac sympathetic nervous system and systolic function by oral beta-blocker therapy in patients with non-ischemic heart disease (NIHD). TWA testing, (123)I-metaiodobenzylguanidine (MIBG) imaging and echocardiography were performed at the baseline and 3 months after beta-blocker therapy in 26 patients with NIHD and positive TWA. The alternans voltage (V(alt)), the heart-to mediastinal-ratio on the early (e-H/M) and delayed (d-H/M) images, the washout rate (WR), the left ventricular ejection fraction (LVEF), and the calculated rate of change by beta-blocker therapy in each parameter (ie, deltaV(alt), deltae-H/M, deltad-H/M, deltaWR and deltaLVEF) were measured. After therapy, TWA turned negative in 8 patients (group A) and remained positive in 18 (group B); V(alt) was significantly decreased in group B (p<0.001). In group A, e-H/M, d-H/M and LVEF were significantly increased (e-H/M: p<0.05, d-H/M and LVEF: p<0.01), as were e-H/M and LVEF in group B (p<0.05). There were significant correlations between deltaV(alt) and deltae-H/M (r=-0.61, p<0.01), deltad-H/M (r=-0.82, p<0.0001), deltaWR (r=0.60, p<0.01) and deltaLVEF (r=-0.70, p<0.01). In patients with NIHD, the TWA is improved in association with the improvement in cardiac sympathetic nervous system abnormalities and left ventricular systolic dysfunction by beta-blocker therapy.
No takes yet. Share an insight, caveat, or question.
Murata et al. (2003) conducted an observational in Non-ischemic heart disease with positive T-wave alternans (n=26). Oral beta-blocker therapy vs. Baseline (pre-therapy) was evaluated on Change in T-wave alternans (TWA) status and alternans voltage (Valt) (p=<0.001). Oral beta-blocker therapy turned T-wave alternans negative in 31% of patients with non-ischemic heart disease and significantly decreased alternans voltage in the remaining patients (p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: